Cervical cancer studies may enroll newly diagnosed locally advanced disease or recurrent/metastatic disease after platinum. HPV status and prior radiation often appear in eligibility. Confirm with the study team using the official NCT contact. Sourced from ClinicalTrials.gov. Not a recommendation to join any study.
RecruitingNot a traditional drug phaseScottsdale, Arizona
Not a traditional drug phase: Quality-of-Life Assessment for Cervical CarcinomaThis early phase I trial compares the side effects between patients treated with proton radiation therapy versus intensity modulated radiation therapy after surgery for the treatment of endometrial or cervical cancer. Radiation therapy uses high energy protons or x-rays to kill tumor cells and shrink tumors.
NCT04567771 · Official ClinicalTrials.gov record · Mayo Clinic
RecruitingNot a traditional drug phasePhoenix, Arizona
Not a traditional drug phase: Vaginal Fluid Collection for Endometrial CancerThe overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in vaginal fluid and 2) ovarian cancer (OC) in plasma and vaginal fluid.
NCT05051722 · Official ClinicalTrials.gov record · Mayo Clinic
RecruitingNot a traditional drug phaseDuarte, California
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseThis is an watch-and-measure (no experimental treatment required) case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid.
NCT05366881 · Official ClinicalTrials.gov record · Adela, Inc
RecruitingPhase 1 / Phase 2Phoenix, Arizona
Phase 1 / Phase 2: testing Rina-S for High Grade Epithelial Ovarian CancerThis study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
NCT05579366 · Official ClinicalTrials.gov record · Genmab
RecruitingPhase 1 / Phase 2Los Angeles, California
Phase 1 / Phase 2: testing STX-478 for Breast CancerStudy STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as this drug alone in participants with advanced solid tumors.
NCT05768139 · Official ClinicalTrials.gov record · Eli Lilly and Company
RecruitingNot a traditional drug phaseLusaka
Not a traditional drug phase: ARROW strategies for Cervical CancerAdolescents and young adults living with HIV experience higher premature mortality from cancer than their uninfected peers. In Zambia, because of multilevel barriers, interventions for early diagnosis and optimized treatment to reduce this cancer mortality are underutilized for this disproportionally impacted cohort.
NCT06004011 · Official ClinicalTrials.gov record · Implenomics
RecruitingPhase 3Birmingham, Alabama
Phase 3: testing Volrustomig for Locally Advanced Cervical CancerThis is a phase III, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, multi-center, global study to explore the how well it works and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.
NCT06079671 · Official ClinicalTrials.gov record · AstraZeneca
RecruitingPhase 2Beijing, Beijing Municipality
Phase 2: testing GT101 for Recurrent or Metastatic Cervical CancerThis is a Phase II, multicenter, open-label, randomly assigned, parallel group, treatment study to assess the how well it works and safety of Autologous Tumor Infiltrating Lymphocytes (GT101 injection) compared with Gemcitabine in participants with recurrent or metastatic cervical cancer.
NCT06241781 · Official ClinicalTrials.gov record · Grit Biotechnology
RecruitingPhase 1Los Angeles, California
Phase 1: testing MGC026 Dose Escalation for Advanced Solid TumorThe study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion in Module A of the study. Combination therapy with pembrolizumab will occur in Module B of the study Participants will receive vobramitamab tavatecan by intravenous (IV) infusion.
NCT06242470 · Official ClinicalTrials.gov record · MacroGenics
RecruitingPhase 1 / Phase 2Orlando, Florida
Phase 1 / Phase 2: testing Two IM injections Lenti-HPV-07 for HPV-Related Cervical CarcinomaThe goal of this clinical trial is to learn about the safety and how well it works of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV). The main questions aim to answer are: * Is Lenti-HPV-07 safe?
NCT06319963 · Official ClinicalTrials.gov record · Theravectys S.A.
RecruitingPhase 1 / Phase 2Los Angeles, California
Phase 1 / Phase 2: testing Ifinatamab deruxtecan for Recurrent or Metastatic Solid TumorsThis study is designed to assess the how well it works and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; cutaneous melanoma; and neuroendocrine carcinoma (NEC).
NCT06330064 · Official ClinicalTrials.gov record · Daiichi Sankyo
RecruitingPhase 1Scottsdale, Arizona
Phase 1: testing Sofe-M for Ovarian NeoplasmsThis study wants to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase 2 (dose expansion).
NCT06400472 · Official ClinicalTrials.gov record · Eli Lilly and Company
RecruitingPhase 1Duarte, California
Phase 1: testing LY4052031 for Metastatic Solid TumorThis study wants to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion).
NCT06465069 · Official ClinicalTrials.gov record · Eli Lilly and Company
RecruitingPhase 2Birmingham, Alabama
Phase 2: testing BAY2927088 for Advanced Solid TumorsResearchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works.
NCT06760819 · Official ClinicalTrials.gov record · Bayer
RecruitingNot a traditional drug phaseDublin, California
Not a traditional drug phase: Exercise intervention for Localized Malignant Solid NeoplasmThis clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength.
NCT07059884 · Official ClinicalTrials.gov record · Alliance for Clinical Trials in Oncology
RecruitingPhase 3Birmingham, Alabama
Phase 3: testing Carboplatin for Locally Advanced Cervical AdenocarcinomaThis phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment of patients with cervical cancer that has spread to nearby tissue or lymph nodes (locally advanced). Carboplatin is in a class of medications known as platinum-containing compounds.
NCT07061977 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
RecruitingPhase 3Birmingham, Alabama
Phase 3: testing Pembrolizumab for Cervical CancerResearchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb).
NCT07216703 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC
RecruitingNot a traditional drug phaseEldoret
Not a traditional drug phase: testing Gardasil-9 for Cervical DysplasiaThis project serves to continue a community-based initiative, known as the Kenya Mother-Daughter Cervical Cancer Eradication Project, or the Mother-Daughter Project (MDP), in the Webuye region of Western Kenya. The MDP project, since its initiation in 2018, has sought to develop a framework for the eradication of cervical cancer through effective screening of adult women and through the vaccination of female children.
NCT07240220 · Official ClinicalTrials.gov record · Indiana University
RecruitingNot a traditional drug phaseKigali
Not a traditional drug phase: Thermal ablation (TA) with 1 probe for HIV (Human Immunodeficiency Virus)Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the World Health Organization (WHO) to treat cervical precancerous lesions, although its how well it works can be suboptimal in WLWH.
NCT07390916 · Official ClinicalTrials.gov record · Fred Hutchinson Cancer Center
RecruitingNot a traditional drug phaseNairobi
Not a traditional drug phase: Thermal ablation (TA) with 1 probe for HIV (Human Immunodeficiency Virus)Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the World Health Organization (WHO) to treat cervical precancerous lesions, although its how well it works can be suboptimal in WLWH.
NCT07468695 · Official ClinicalTrials.gov record · Fred Hutchinson Cancer Center
RecruitingPhase 1Los Angeles, California
Phase 1: testing RGT-490 for Breast CancerThis is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to measure the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors including breast cancer. Participants enrolled in the study have advanced disease that is not amendable to curative treatment and whose tumors harbor alterations in the PI3KCA gene.
NCT07524322 · Official ClinicalTrials.gov record · Regor Pharmaceuticals Inc.
RecruitingNot a traditional drug phaseHouston, Texas
Not a traditional drug phase: Questionnaire for Neuroendocrine Cervical CancerTo learn about the effects of a participant support community on illness perception, emotional well-being, and feelings of isolation among participants with NECC.
NCT07532954 · Official ClinicalTrials.gov record · M.D. Anderson Cancer Center
RecruitingNot a traditional drug phaseHarare
Not a traditional drug phase: Thermal ablation (TA) with 1 probe for HIV (Human Immunodeficiency Virus)Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. While thermal ablation (TA) is a WHO- recommended treatment for cervical precancerous lesions, its how well it works can be suboptimal in WLWH.
NCT07645352 · Official ClinicalTrials.gov record · Fred Hutchinson Cancer Center
RecruitingNot a traditional drug phaseHuai'an, Jiangsu
Not a traditional drug phase: testing DEX 0.2 μg/kg/h. for Uterine Fibroids (Leiomyoma)Study Objectives This study aims to investigate the effects of preoperative stellate ganglion block and intraoperative intravenous dexmedetomidine on postoperative sleep disturbance in patients undergoing laparoscopic gynecologic surgery, with the goals of reducing pain and postoperative adverse reactions and identifying an effective, safe, economical, and broadly applicable intervention strategy that may facilitate emergence from anesthesia, accelerate postoperative recovery, shorten the length of hospital stay, and reduce hospitalization costs. This trial aims to determine whether preoperative stellate ganglion block (SGB) and intraoperative intravenous dexmedetomidine (DEX) can improve postoperative sleep quality in patients undergoing laparoscopic gynecologic surgery, and whether the combination of these two interventions provides an interaction effect or additional ben
NCT07860203 · Official ClinicalTrials.gov record · Catherin Zhang
RecruitingNot a traditional drug phaseNairobi
Not a traditional drug phase: HPV DNA Testing (Abbott Alinity m HPV Assay) for Human Papillomavirus (HPV)The overall goal of this study is to inform the design and establish feasibility for a future clinical trial to determine the optimal management of women living with HIV (WLWH) with high-risk human papillomavirus (hrHPV) detected on HPV-based cervical cancer screening. WLWH have a higher diversity of anogenital HPV types causing cervical high-grade squamous intraepithelial lesions (hHSIL) and invasive cancer compared to women without HIV.
NCT07925307 · Official ClinicalTrials.gov record · University of California, San Diego